Revolution Medicines
Preço: 153.87Empresa e modelo de negócios
Revolution Medicines is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. Its core products include small molecule inhibitors designed to address specific genetic mutations in tumors. The company operates primarily in the healthcare sector, with major revenue sources stemming from partnerships, collaborations, and potential future product sales.
Perfil de investimento
The investment profile of Revolution Medicines may appeal more to growth investors due to its focus on innovative therapies and potential for future revenue generation. However, the high risk associated with its current financial performance and lack of profitability suggests caution. The stock may not be suitable for dividend or value investors at this time.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -7.11 Risco
- Surpresa de EPS
- -25.1% pior que o esperado
- Volatilidade 20d
- 2.8% estável
Impacto da previsão
neutroAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:51 | Manter | Vender | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:58 | Vender | Manter | High growth but significant losses and uncertainty remain. |
| 2026-05-08 14:57 | — | Vender | Weak fundamentals and negative momentum raise significant risk. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-09 13:24 | UBS | Atualizar | — → 175 | 148.4461 |
| 2026-06-02 09:03 | RBC Capital | Preço-alvo elevado | — → 182 | 163.68 |
| 2026-06-01 14:33 | H.C. Wainwright | Preço-alvo elevado | 169 → 195 | 162.51 |
Nada ainda